Clinical Trial News and Research

RSS

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that it conducted a formal clinical guidance meeting with the U.S. FDA to determine the most expeditious U.S. registration pathway for BiovaxID, its personalized cancer vaccine for the consolidation treatment of follicular non-Hodgkin's lymphoma.

15 Aug 2012

New tool reveals surprising clues about how cancer cells respond to therapy

A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy - and may offer a way to further refine personalized cancer treatments.

15 Aug 2012

TAIN project aims to optimise treatment for babies with adrenal insufficiency

Groundbreaking research into rare neonatal diseases, conducted by the University of Sheffield, is set to improve the treatment of babies who lack the stress hormone cortisol.

15 Aug 2012

Schizophrenia and the immune system: an interview with Prof Cyndi Shannon Weickert

Schizophrenia is the most disabling disease impacting youth today. It impacts 1% of the total population and typically causes withdrawal from society, loss in IQ, disordered thought and speech, hallucinations and delusions.

14 Aug 2012

Latrepiridine reduces level of at least two neurodegeneration-related proteins in mice

14 Aug 2012

Researchers identify molecular pathway by which Notch regulates cell proliferation in lung cancer

Lung cancer is one of the most aggressive types of cancer and the most common cause of death from this disease worldwide. Despite the progress in the molecular biology of lung cancer achieved in recent years, the mechanisms used by tumor cells to grow and spread throughout the body are not yet completely understood. This lack of information is responsible for the limited range of available therapeutic possibilities and their undesirable side effects.

14 Aug 2012

CBIS initiates CS-TATI-1 GMP development plan

Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical to meet global public health challenges is pleased to announce the initiation of GMP development plan for CS-TATI-1 with the initial production of CS-TATI-1 to be performed in Colorado under C-GMP conditions evaluated by the FDA for initial human studies to treat HIV associated Kaposi Sarcoma.

13 Aug 2012

Latrepirdine demonstrates new potential against neurodegenerative conditions

The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice.

13 Aug 2012

Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

Meritage Pharma, Inc. announced that it has initiated a Phase 2 clinical trial to evaluate oral budesonide suspension (OBS) for the treatment of adolescents and young adults with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation.

13 Aug 2012

FDA clears Stryker’s Trevo Pro Retriever to treat acute ischemic stroke

Stryker Neurovascular announced today that its Trevo Pro Retriever has been granted 510(k) market clearance by the U.S. Food and Drug Administration. The Trevo Pro Retriever is the next generation in clot removal technology from Stryker, utilizing proprietary Stentriever Technology for optimized clot integration and retrieval in patients experiencing acute ischemic stroke.

From Stryker 13 Aug 2012

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness

12 Aug 2012

Resistant starch can help improve insulin sensitivity

Ingredion Incorporated, a leading global provider of ingredient solutions, today announced the results of a new independent clinical trial published in the September 2012 issue of the Journal of Clinical Endocrinology & Metabolism.

10 Aug 2012

FDA approved drug to treat Ph- acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing form of blood and bone marrow cancer that is more commonly diagnosed in children than adults.

10 Aug 2012

Technology for assessing Bradykinesia response to novel therapies in Parkinson’s Disease to be developed by Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they have received $1.5 million in funding to commercialize a technology for Parkinson’s disease (PD) patients that will better assess motor symptoms in response to new deep brain stimulation (DBS) and pharmaceutical therapies.

8 Aug 2012

GTx reports revenue of $1.6 million for second quarter 2012

GTx, Inc. today provided a Company update and reported financial results for the second quarter of 2012.

8 Aug 2012

Omeros completes enrollment in first of two OMS103HP Phase 3 meniscectomy trials

Omeros Corporation today reported the completion of enrollment in the first of two planned Phase 3 clinical trials evaluating OMS103HP in patients undergoing arthroscopic partial meniscectomy surgery.

8 Aug 2012

HCRI announces successful completion of randomization in DAPT Study

The Harvard Clinical Research Institute (HCRI) announced today the successful completion of randomization in the DAPT Study, with the total number of patients randomized exceeding the upper goal set for the Study.

8 Aug 2012

Neutral-pressure IV connector eliminates catheter-related bloodstream infections in cancer patients

A neutral-pressure IV needleless connector was associated with complete elimination of catheter-related bloodstream infections (CRBSI) in a successful device trial at a large cancer center in the six-month period following implementation of the device.

8 Aug 2012

New clinical trial to study how worm eggs may relieve symptoms of ulcerative colitis

A new clinical trial designed to study how worm eggs may relieve symptoms of ulcerative colitis (UC) will begin enrolling patients at NYU School of Medicine's Clinical and Translational Science Institute. This unusual therapy has been used in previous clinical trials on patients with inflammatory bowel diseases, but the mechanism of action is unclear.

8 Aug 2012

Study reports new potential NOX inhibitor therapy for liver fibrosis

A study published in the online journal Hepatology reports a potential new NADPH oxidase (NOX) inhibitor therapy for liver fibrosis, a scarring process associated with chronic liver disease that can lead to loss of liver function.

8 Aug 2012

Clinical Trial News and Research

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

New tool reveals surprising clues about how cancer cells respond to therapy

TAIN project aims to optimise treatment for babies with adrenal insufficiency

Schizophrenia and the immune system: an interview with Prof Cyndi Shannon Weickert

Latrepiridine reduces level of at least two neurodegeneration-related proteins in mice

Researchers identify molecular pathway by which Notch regulates cell proliferation in lung cancer

CBIS initiates CS-TATI-1 GMP development plan

Latrepirdine demonstrates new potential against neurodegenerative conditions

Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

FDA clears Stryker’s Trevo Pro Retriever to treat acute ischemic stroke

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Resistant starch can help improve insulin sensitivity

FDA approved drug to treat Ph- acute lymphoblastic leukemia

Technology for assessing Bradykinesia response to novel therapies in Parkinson’s Disease to be developed by Great Lakes NeuroTechnologies

GTx reports revenue of $1.6 million for second quarter 2012

Omeros completes enrollment in first of two OMS103HP Phase 3 meniscectomy trials

HCRI announces successful completion of randomization in DAPT Study

Neutral-pressure IV connector eliminates catheter-related bloodstream infections in cancer patients

New clinical trial to study how worm eggs may relieve symptoms of ulcerative colitis

Study reports new potential NOX inhibitor therapy for liver fibrosis

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer